Publication | Closed Access
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma
36
Citations
17
References
2020
Year
Crenigacestat demonstrated limited clinical activity at the recommended dose in adult patients with relapsed/refractory T-ALL/T-LBL.
| Year | Citations | |
|---|---|---|
Page 1
Page 1